A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-06 and is reviewed periodically as new material appears.
After a peptide solution is prepared, its handling conditions influence how long it remains suitable for use. Solutions are typically separated into small portions to avoid repeated freeze-thaw cycles, which can promote aggregation or precipitation. Containers are chosen to minimize adsorption, especially for peptides that are hydrophobic or present at low concentration. Some laboratories use low-binding plastic tubes or add a carrier protein, although carrier addition can interfere with later analysis. Records usually note the solvent, date, and storage temperature for traceability.
Storage stability of a reconstituted peptide depends on concentration, pH, buffer composition, and the presence of oxygen or microbial contaminants. Short-term storage is often at refrigerated temperatures, while longer-term storage may use freezing at -20 °C or -80 °C. Repeated warming and cooling can cause losses through adsorption or aggregation, so aliquots are preferred. Light-sensitive peptides require protection from ambient light. Sterile filtration may be used when microbial control is needed, but filters can adsorb peptides and reduce recovery.
Quality control after reconstitution usually includes visual inspection and instrumental analysis. A clear, particle-free solution is generally expected, but color and clarity can vary with sequence and buffer. Chromatographic separation can detect degradation products, while mass confirmation verifies molecular identity. pH measurement and osmolality checks may be relevant for certain applications. Documentation of lot number, solvent, and storage history supports reproducibility and helps distinguish preparation artifacts from sample degradation. Temperature logs and freeze-thaw counts add further context when results are reviewed.
Once a peptide is in liquid form, its stability depends on temperature, pH, concentration, and the presence of oxygen or microbes. Refrigeration slows many degradation pathways, while freezing can extend storage for longer periods. Repeated freeze-thaw cycles are generally avoided because ice crystal formation and concentration changes can promote aggregation. Light exposure can also damage peptides that contain aromatic or sulfur-containing residues. A common laboratory practice is to divide a reconstituted stock into single-use aliquots before freezing, but the optimal storage condition remains peptide-specific and is often determined empirically.
Analytical checks help determine whether a reconstituted peptide matches its expected identity and purity; reverse-phase high-performance liquid chromatography separates components by hydrophobicity and can reveal degradation products or impurities. Mass spectrometry provides a mass measurement that supports sequence identity when compared with the theoretical value. Ultraviolet absorbance at 280 nm can estimate concentration for peptides containing tryptophan or tyrosine, though sequence-dependent extinction coefficients are needed. For shorter or non-aromatic peptides, other methods such as amino acid analysis may be required. These techniques describe the material rather than guarantee its biological effect.
Cloudiness, particles, or gel formation after reconstitution can signal incomplete dissolution, aggregation, or contamination. A clear solution is not proof of purity, and a cloudy one is not always unusable if the peptide is designed to form suspensions. pH measurement can identify whether the solution matches the intended range, and buffer exchange may be needed when the original solvent is incompatible. Sterile filtration is sometimes used for microbial control, but filters can adsorb peptides and reduce concentration. Documentation of lot number, solvent, volume, date, and storage condition supports later traceability in laboratory records.
| Property | Value | Notes |
|---|---|---|
| Appearance | Clear to slightly opalescent | Opalescence may indicate aggregation or undissolved material |
| Typical pH range | 3–7 for many peptides | Depends on sequence and buffer; measured after dissolution |
| Storage temperature (short term) | 2–8 °C | Refrigerated; limit repeated warming |
| Storage temperature (long term) | -20 °C or -80 °C | Freezing recommended for many research peptides |
| Common analytical method | RP-HPLC with UV detection | Purity and degradation profile can be monitored |
Once a peptide is dissolved, its solution is generally less stable than the dry powder. Chemical pathways such as hydrolysis, oxidation, and deamidation can alter the molecule, while physical processes can form aggregates or cause adsorption to container walls. The rate depends on pH, buffer composition, temperature, concentration, and the specific sequence. Aqueous stocks are therefore kept cold and used within a defined period. Stability testing is usually performed for each peptide rather than assumed from a general rule.
Cold storage slows most degradation but does not stop it. Reconstituted solutions are commonly divided into aliquots and held at -20 °C or -80 °C, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or precipitation, so single-use aliquots are preferred. Some peptides tolerate refrigeration for short intervals, while others require freezing immediately. Light-sensitive residues may need amber or foil-wrapped containers. The optimal condition remains peptide-specific and should be supported by stability data.
After a peptide is reconstituted, handling practices affect its chemical and physical stability over time. Aqueous solutions can support microbial growth unless they are prepared with aseptic technique or contain preservatives. Container material matters because peptides can adsorb to glass or plastic surfaces, reducing the amount available in solution. Repeated transfers increase exposure to air and potential contaminants, and temperature fluctuations can accelerate degradation. These factors are separate from the peptide's intrinsic sequence-based stability.
Storage conditions for reconstituted peptides are product-specific. Cool temperatures slow many degradation pathways, but freezing can concentrate solutes and promote aggregation. Light exposure can oxidize susceptible residues such as methionine, cysteine, or tryptophan. Oxygen in headspace can contribute to oxidation, while acidic or basic pH can drive hydrolysis and deamidation. The best storage condition for a given sequence is often determined empirically because general rules do not capture all sequence-specific effects.
==== Variation between animal species ==== Studies on the cell membranes of mammals and reptiles discovered that mammalian cell membranes are composed of a higher proportion of polyunsaturated fatty acids (DHA, omega−3 fatty acid) than reptiles. Studies on bird fatty acid composition have noted similar proportions to mammals but with 1/3rd less omega−3 fatty acids as compared to omega−6 for a given body size. This fatty acid composition results in a more fluid cell membrane but also one that is permeable to various ions (H+ & Na+), resulting in cell membranes that are more costly to maintain. This maintenance cost has been argued to be one of the key causes for the high metabolic rates and concomitant warm-bloodedness of mammals and birds. However polyunsaturation of cell membranes may also occur in response to chronic cold temperatures as well. In fish increasingly cold environments lead to increasingly high cell membrane content of both monounsaturated and polyunsaturated fatty acids, to maintain greater membrane fluidity (and functionality) at the lower temperatures.
== History == Zydis technology was developed by R.P. Scherer Corporation (currently owned by Catalent Pharma Solutions) in 1986. The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine (famotidine) from Merck & Co. was launched in Sweden. In November 1993 Imodium Lingual (loperamide) from Janssen Pharmaceutica was released in Germany with Zydis technology. In December, 1996, the Food and Drug Administration approved Claritin (loratadine) RediTabs from Schering-Plough, the first prescription drug with Zydis technology sold in the U.S.
==== MeSH D13.570.583 – purine nucleosides ==== MeSH D13.570.583.138 – adenosine MeSH D13.570.583.138.025 – adenosine-5'-(n-ethylcarboxamide) MeSH D13.570.583.138.240 – s-adenosylhomocysteine MeSH D13.570.583.138.264 – s-adenosylmethionine MeSH D13.570.583.138.300 – 2-chloroadenosine MeSH D13.570.583.138.300.200 – cladribine MeSH D13.570.583.138.325 – deoxyadenosines MeSH D13.570.583.138.325.075 – cladribine MeSH D13.570.583.138.325.105 – dideoxyadenosine MeSH D13.570.583.138.325.800 – puromycin aminonucleoside MeSH D13.570.583.138.500 – isopentenyladenosine MeSH D13.570.583.138.630 – phenylisopropyladenosine MeSH D13.570.583.138.711 – puromycin MeSH D13.570.583.138.711.650 – puromycin aminonucleoside MeSH D13.570.583.138.900 – vidarabine MeSH D13.570.583.454 – guanosine MeSH D13.570.583.454.240 – deoxyguanosine MeSH D13.570.583.454.500 – nucleoside q MeSH D13.570.583.616 – inosine MeSH D13.570.583.616.130 – didanosine MeSH D13.570.583.616.450 – inosine pranobex MeSH D13.570.583.616.900 – thioinosine MeSH D13.570.583.616.900.500 – methylthioinosine MeSH D13.570.583.910 – tubercidin
Sources: en.wikipedia.org
In 1905, the Cossack hosts experienced deep mobilization of their menfolk amid the fighting of the Russo-Japanese War in Manchuria and the outbreak of revolution within the Russian Empire. Like other peoples of the empire, some Cossack stanitsas voiced grievances against the regime by defying mobilization orders, or by making relatively liberal political demands. But these infractions were eclipsed by the prominent role of Cossack detachments in stampeding demonstrators and restoring order in the countryside. Subsequently, the wider population viewed the Cossacks as instruments of reaction. Tsar Nicholas II reinforced this concept by issuing new charters, medals, and bonuses to Cossack units in recognition for their performance during the Revolution of 1905. In September 1906, reflecting the success of the Cossacks in putting down the Revolution of 1905, Polkovnik (Colonel) Vladimir Liakhov was sent to Iran to command the train and lead the Persian Cossack Brigade. Liakhov had led a Cossack squad in putting down the revolution in the Caucasus, and following the outbreak of the Constitutional Revolution in Iran he was sent to Tehran to recognize the Cossack Brigade as a force for power to the shah. The Persian Cossack Brigade had not been paid for months and proved to be dubious loyalty to the House of Qajar during the Constructional revolution while its Russian officers were uncertain what to do with Russia itself in revolution.
==== Photoreception ==== In 2015, molecular evidence was published indicating that cephalopod chromatophores are photosensitive; reverse transcription polymerase chain reactions (RT-PCR) revealed transcripts encoding rhodopsin and retinochrome within the retinas and skin of the longfin inshore squid (Doryteuthis pealeii), and the common cuttlefish (Sepia officinalis) and broadclub cuttlefish (Sepia latimanus). The authors claim this is the first evidence that cephalopod dermal tissues may possess the required combination of molecules to respond to light.
== Therapeutic applications == Given the ability to knock down, in essence, any gene of interest, RNAi via siRNAs presents opportunities in both basic and applied biology. One of the biggest challenges to siRNA and RNAi-based therapeutics is intracellular delivery. siRNA also has weak stability and pharmacokinetic behavior. Delivery of siRNA via nanoparticles has shown promise. siRNA oligos in vivo are vulnerable to degradation by plasma and tissue endonucleases and exonucleases and have shown only mild effectiveness in localized delivery sites, such as the human eye. Delivering pure DNA to target organisms is challenging because its large size and structure prevent it from diffusing readily across membranes. siRNA oligos circumvent this problem due to their small size of 21–23 nucleotides. This allows delivery via nano-scale delivery vehicles called nanovectors. A good nanovector for siRNA delivery should protect siRNA from degradation, enrich siRNA in the target organ, and facilitate the cellular uptake of siRNA. The three main groups of siRNA nanovectors are: lipid based, non-lipid organic-based, and inorganic. Lipid based nanovectors are excellent for delivering siRNA to solid tumors, but other cancers may require different non-lipid based organic nanovectors such as cyclodextrin based nanoparticles. siRNAs delivered via lipid based nanoparticles have been shown to have therapeutic potential for central nervous system (CNS) disorders.
Sources: en.wikipedia.org
Refrigeration is common for short-term use, while freezing at -20 °C or -80 °C is common for longer periods. Aliquots reduce repeated temperature changes. Exact conditions depend on the peptide and buffer.
Repeated freeze-thaw cycles can cause aggregation, precipitation, or adsorption losses. Dividing a solution into single-use portions limits those changes. The practice also makes handling more consistent.
Undissolved powder, aggregated peptide, or precipitated buffer salts can produce visible particles. Some particles appear only after freezing or pH changes. Filtration and analytical checks can help identify the source.
Short-term storage is often under refrigeration, while longer storage may use freezing at -20 °C or lower. The choice depends on peptide stability and the solvent. Dividing the solution into aliquots reduces repeated temperature changes.